Document:

<PAGE>   1

                                                                     EXHIBIT 4.4

                         REGISTRATION RIGHTS AGREEMENT

        This REGISTRATION RIGHTS AGREEMENT (this "Agreement") is made of August
11, 2000 by and among (i) Coulter Pharmaceutical, Inc., a Delaware corporation
(the "Company"), (ii) each person listed on Exhibit A attached hereto
(collectively, the "Initial Investors" and each individually, an "Initial
Investor"), and (iii) each person or entity that subsequently becomes a party to
this Agreement pursuant to, and in accordance with, the provisions of Section 12
hereof (collectively, the "Investor Permitted Transferees" and each individually
an "Investor Permitted Transferee").

        WHEREAS, the Company has agreed to issue and sell to the Initial
Investors, and the Initial Investors have agreed to purchase from the Company,
1,655,000 shares (the "Purchased Shares") of the Company's common stock, $0.001
par value per share (the "Common Stock"), all upon the terms and conditions set
forth in that certain Stock Purchase Agreement, dated of even date herewith,
between the Company and the Initial Investors (the "Stock Purchase Agreement");
and

        WHEREAS, the terms of the Stock Purchase Agreement provide that it shall
be a condition precedent to the closing of the transactions thereunder, for the
Company and the Initial Investors to execute and deliver this Agreement.

        NOW, THEREFORE, in consideration of the premises and mutual covenants
contained herein, the parties hereto hereby agree as follows:

        1. DEFINITIONS. The following terms shall have the meanings provided
therefor below or elsewhere in this Agreement as described below:

             "BOARD" shall mean the board of directors of the Company.

             "CLOSING" shall have the meaning ascribed to such term in the Stock
Purchase Agreement.

             "EXCHANGE ACT" shall mean the Securities Exchange Act of 1934, as
amended, and all of the rules and regulations promulgated thereunder.

             "INVESTORS" shall mean, collectively, the Initial Investors and the
Investor Permitted Transferees; provided, however, that the term "Investors"
shall not include any of the Initial Investors or any of the Investor Permitted
Transferees that ceases to own or hold any Purchased Shares.

             "MAJORITY HOLDERS" shall mean, at the relevant time of reference
thereto, those Investors holding and/or having the right to acquire, as the case
may be, more than fifty percent (50%) of the Registrable Shares held by all of
the Investors.

             "QUALIFYING HOLDER" shall have the meaning ascribed thereto in
Section 12 hereof.

                                       1.
<PAGE>   2

             "REGISTRABLE SHARES" shall mean the Purchased Shares, provided,
however, such term shall not, after the Mandatory Registration Termination Date,
include any of the Purchased Shares that become or have become eligible for
resale pursuant to Rule 144 or pursuant to Regulation S.

             "RULE 144" shall mean Rule 144 promulgated under the Securities Act
and any successor or substitute rule, law or provision.

             "SEC" shall mean the Securities and Exchange Commission.

             "SECURITIES ACT" shall mean the Securities Act of 1933, as amended,
and all of the rules and regulations promulgated thereunder.

        2. EFFECTIVENESS; TERMINATION. This Agreement shall become effective and
legally binding only if the Closing occurs. This Agreement shall terminate and
be of no further force or effect, automatically and without any action being
required of any party hereto, upon the termination of the Stock Purchase
Agreement pursuant to Section 7 thereof.

        3. MANDATORY REGISTRATION.

             (a) On or prior to August 30, 2000, the Company will prepare and
file with the SEC a registration statement on Form S-3, for the purpose of
registering under the Securities Act all of the Registrable Shares for resale
by, and for the account of, the Investors as selling stockholders thereunder
(the "Registration Statement"). The Registration Statement shall permit the
Investors to offer and sell, on a delayed or continuous basis pursuant to Rule
415 under the Securities Act, any or all of the Registrable Shares. The Company
agrees to use reasonable efforts to cause the Registration Statement to become
effective as soon as practicable. The Company shall be required to keep the
Registration Statement effective until such date that is the earlier of (i) the
date when all of the Registrable Shares registered thereunder shall have been
sold or (ii) the second anniversary of the Closing, subject to extension as set
forth below (such date is referred to herein as the "Mandatory Registration
Termination Date"). Thereafter, the Company shall be entitled to withdraw the
Registration Statement and the Investors shall have no further right to offer or
sell any of the Registrable Shares pursuant to the Registration Statement (or
any prospectus relating thereto). In the event the right of the selling
Investors to use the Registration Statement (and the prospectus relating
thereto) is delayed or suspended pursuant to Sections 4(c) or 10 hereof, the
Company shall be required to extend the Mandatory Registration Termination Date
beyond the second anniversary of the Closing by the same number of days as such
delay, or Suspension Period (as defined in Section 10 hereof).

             (b) The offer and sale of the Registrable Shares pursuant to the
Registration Statement shall not be underwritten.

        4. OBLIGATIONS OF THE COMPANY. In connection with the Company's
obligation under Section 3 and hereof to file the Registration Statement with
the SEC and to use its best efforts to cause the Registration Statement to
become effective as soon as practicable, the Company shall, as expeditiously as
reasonably possible:

                                       2.
<PAGE>   3

             (a) Prepare and file with the SEC such amendments and supplements
to the Registration Statement and the prospectus used in connection therewith as
may be necessary to comply with the provisions of the Securities Act with
respect to the disposition of all Registrable Shares covered by the Registration
Statement;

             (b) Furnish to the selling Investors such number of copies of a
prospectus, including a preliminary prospectus, in conformity with the
requirements of the Securities Act, and such other documents (including, without
limitation, prospectus amendments and supplements as are prepared by the Company
in accordance with Section 4(a) above) as the selling Investors may reasonably
request in order to facilitate the disposition of such selling Investors'
Registrable Shares;

             (c) Notify the selling Investors, at any time when a prospectus
relating to the Registration Statement is required to be delivered under the
Securities Act, of the happening of any event as a result of which the
prospectus included in or relating to the Registration Statement contains an
untrue statement of a material fact or omits any fact necessary to make the
statements therein not misleading; and, thereafter, the Company will promptly
prepare (and, when completed, give notice to each selling Investor) a supplement
or amendment to such prospectus so that, as thereafter delivered to the
purchasers of such Registrable Shares, such prospectus will not contain an
untrue statement of a material fact or omit to state any fact necessary to make
the statements therein not misleading; provided that upon such notification by
the Company, the selling Investors will not offer or sell Registrable Shares
until the Company has notified the selling Investors that it has prepared a
supplement or amendment to such prospectus and delivered copies of such
supplement or amendment to the selling Investors (it being understood and agreed
by the Company that the foregoing proviso shall in no way diminish or otherwise
impair the Company's obligation to promptly prepare a prospectus amendment or
supplement as above provided in this Section 4(c) and deliver copies of same as
above provided in Section 4(b) hereof); and

             (d) Use commercially reasonable efforts to register and qualify the
Registrable Shares covered by the Registration Statement under such other
securities or Blue Sky laws of such jurisdictions as shall be reasonably
appropriate in the opinion of the Company and the placement agents, if any,
provided that the Company shall not be required in connection therewith or as a
condition thereto to qualify to do business or to file a general consent to
service of process in any such states or jurisdictions, and provided further
that (notwithstanding anything in this Agreement to the contrary with respect to
the bearing of expenses) if any jurisdiction in which any of such Registrable
Shares shall be qualified shall require that expenses incurred in connection
with the qualification therein of any such Registrable Shares be borne by the
selling Investors, then the selling Investors shall, to the extent required by
such jurisdiction, pay their pro rata share of such qualification expenses.

        5. FURNISH INFORMATION. It shall be a condition precedent to the
obligations of the Company to take any action pursuant to this Agreement that
the selling Investors shall furnish to the Company such information regarding
them and the securities held by them as the Company shall reasonably request and
as shall be required in order to effect any registration by the Company pursuant
to this Agreement.

                                       3.
<PAGE>   4

        6. EXPENSES OF REGISTRATION. All expenses incurred in connection with
the registration of the Registrable Shares pursuant to this Agreement (excluding
underwriting, brokerage and other selling commissions and discounts), including
without limitation all registration and qualification and filing fees, printing,
and fees and disbursements of counsel for the Company, shall be borne by the
Company.

        7. DELAY OF REGISTRATION. The Investors shall not take any action to
restrain, enjoin or otherwise delay any registration as the result of any
controversy which might arise with respect to the interpretation or
implementation of this Agreement.

        8. INDEMNIFICATION.

             (a) To the extent permitted by law, the Company will indemnify and
hold harmless each selling Investor, any investment banking firm acting as an
underwriter for the selling Investors, any broker/dealer acting on behalf of any
selling Investors and each officer and director of such selling Investor, such
underwriter, such broker/dealer and each person, if any, who controls such
selling Investor, such underwriter or broker/dealer within the meaning of the
Securities Act, against any losses, claims, damages or liabilities, joint or
several, to which they may become subject under the Securities Act or otherwise,
insofar as such losses, claims, damages or liabilities (or actions in respect
thereof) arise out of or are based upon any untrue or alleged untrue statement
of any material fact contained in the Registration Statement, in any preliminary
prospectus or final prospectus relating thereto or in any amendments or
supplements to the Registration Statement or any such preliminary prospectus or
final prospectus, or arise out of or are based upon the omission or alleged
omission to state therein a material fact required to be stated therein, or
necessary to make the statements therein not misleading; and will reimburse such
selling Investor, such underwriter, broker/dealer or such officer, director or
controlling person for any legal or other expenses reasonably incurred by them
in connection with investigating or defending any such loss, claim, damage,
liability or action; provided, however, that the indemnity agreement contained
in this Section 8(a) shall not apply to amounts paid in settlement of any such
loss, claim, damage, liability or action if such settlement is effected without
the consent of the Company (which consent shall not be unreasonably withheld),
nor shall the Company be liable in any such case for any such loss, damage,
liability or action to the extent that it arises out of or is based upon an
untrue statement or alleged untrue statement or omission made in connection with
the Registration Statement, any preliminary prospectus or final prospectus
relating thereto or any amendments or supplements to the Registration Statement
or any such preliminary prospectus or final prospectus, in reliance upon and in
conformity with written information furnished expressly for use in connection
with the Registration Statement or any such preliminary prospectus or final
prospectus by the selling Investors, any underwriter for them or controlling
person with respect to them.

             (b) To the extent permitted by law, each selling Investor will
severally and not jointly indemnify and hold harmless the Company, each of its
directors, each of its officers who have signed the Registration Statement, each
person, if any, who controls the Company within the meaning of the Securities
Act, any investment banking firm acting as underwriter for the Company or the
selling Investors, or any broker/dealer acting on behalf of the Company or any
selling Investors, and all other selling Investors against any losses, claims,
damages or liabilities to which the Company or any such director, officer,
controlling person, underwriter, or

                                       4.
<PAGE>   5

broker/dealer or such other selling Investor may become subject to, under the
Securities Act or otherwise, insofar as such losses, claims, damages or
liabilities (or actions in respect thereto) arise out of or are based upon any
untrue or alleged untrue statement of any material fact contained in the
Registration Statement or any preliminary prospectus or final prospectus,
relating thereto or in any amendments or supplements to the Registration
Statement or any such preliminary prospectus or final prospectus, or arise out
of or are based upon the omission or alleged omission to state therein a
material fact required to be stated therein or necessary to make the statements
therein not misleading, in each case to the extent and only to the extent that
such untrue statement or alleged untrue statement or omission or alleged
omission was made in the Registration Statement, in any preliminary prospectus
or final prospectus relating thereto or in any amendments or supplements to the
Registration Statement or any such preliminary prospectus or final prospectus,
in reliance upon and in conformity with written information furnished by the
selling Investor expressly for use in connection with the Registration
Statement, or any preliminary prospectus or final prospectus; and such selling
Investor will reimburse any legal or other expenses reasonably incurred by the
Company or any such director, officer, controlling person, underwriter,
broker/dealer or other selling Investor in connection with investigating or
defending any such loss, claim, damage, liability or action, provided, however,
that the liability of each selling Investor hereunder shall be limited to the
proceeds (net of underwriting discounts and commissions, if any) received by
such selling Investor from the sale of Registrable Shares covered by the
Registration Statement, and provided, further, however, that the indemnity
agreement contained in this Section 8(b) shall not apply to amounts paid in
settlement of any such loss, claim, damage, liability or action if such
settlement is effected without the consent of those selling Investor(s) against
which the request for indemnity is being made (which consent shall not be
unreasonably withheld).

             (c) Promptly after receipt by an indemnified party under this
Section 8 of notice of the commencement of any action, such indemnified party,
will, if a claim in respect thereof is to be made against any indemnifying party
under this Section 8, notify the indemnifying party in writing of the
commencement thereof and the indemnifying party shall have the right to
participate in and, to the extent the indemnifying party desires, jointly with
any other indemnifying party similarly noticed, to assume at its expense the
defense thereof with counsel mutually satisfactory to the indemnifying parties
with the consent of the indemnified party which consent will not be unreasonably
withheld, conditioned or delayed. In the event that the indemnifying party
assumes any such defense, the indemnified party may participate in such defense
with its own counsel and at its own expense, provided, however, that the counsel
for the indemnifying party shall act as lead counsel in all matters pertaining
to such defense or settlement of such claim and the indemnifying party shall
only pay for such indemnified party's expenses for the period prior to the date
of its participation on such defense. The failure to notify an indemnifying
party promptly of the commencement of any such action, if prejudicial to his
ability to defend such action, shall relieve such indemnifying party of any
liability to the indemnified party under this Section 8, but the omission so to
notify the indemnifying party will not relieve him of any liability which he may
have to any indemnified party otherwise other than under this Section 8.

             (d) Notwithstanding anything to the contrary herein, the
indemnifying party shall not be entitled to settle any claim, suit or proceeding
unless in connection with such settlement the indemnified party receives an
unconditional release with respect to the subject

                                       5.
<PAGE>   6

matter of such claim, suit or proceeding and such settlement does not contain
any admission of fault by the indemnified party.

        9. REPORTS UNDER THE EXCHANGE ACT. With a view to making available to
the Investors the benefits of Rule 144 and any other rule or regulation of the
SEC that may at any time permit the Investors to sell the Purchased Shares to
the public without registration, the Company agrees to use commercially
reasonable efforts: (i) to make and keep public information available, as those
terms are understood and defined in the General Instructions to Form S-3, or any
successor or substitute form, and in Rule 144, (ii) to file with the SEC in a
timely manner all reports and other documents required to be filed by an issuer
of securities registered under the Securities Act or the Exchange Act, (iii) as
long as any Investor owns any Purchased Shares, to furnish in writing upon such
Investor's request a written statement by the Company that it has complied with
the reporting requirements of Rule 144 and of the Securities Act and the
Exchange Act, and to furnish to such Investor a copy of the most recent annual
or quarterly report of the Company, and such other reports and documents so
filed by the Company as may be reasonably requested in availing such Investor of
any rule or regulation of the SEC permitting the selling of any such Purchased
Shares without registration and (iv) undertake any additional actions reasonably
necessary to maintain the availability of the Registration Statement or the use
of Rule 144.

        10. DEFERRAL AND LOCK-UP.

             (a) Notwithstanding anything in this Agreement to the contrary, if
the Company shall furnish to the selling Investors a certificate signed by the
President or Chief Executive Officer of the Company stating that the Board of
Directors of the Company has made the good faith determination (i) that
continued use by the selling Investors of the Registration Statement for
purposes of effecting offers or sales of Registrable Shares pursuant thereto
would require, under the Securities Act, premature disclosure in the
Registration Statement (or the prospectus relating thereto) of material,
nonpublic information concerning the Company, its business or prospects or any
proposed material transaction involving the Company, (ii) that such premature
disclosure would be materially adverse to the Company, its business or prospects
or any such proposed material transaction or would make the successful
consummation by the Company of any such material transaction significantly less
likely and (iii) that it is therefore essential to suspend the use by the
Investors of such Registration Statement (and the prospectus relating thereto)
for purposes of effecting offers or sales of Registrable Shares pursuant
thereto, then the right of the selling Investors to use the Registration
Statement (and the prospectus relating thereto) for purposes of effecting offers
or sales of Registrable Shares pursuant thereto shall be suspended for a period
(the "Suspension Period") of not more than 90 days after delivery by the Company
of the certificate referred to above in this Section 10. During the Suspension
Period, none of the Investors shall offer or sell any Registrable Shares
pursuant to or in reliance upon the Registration Statement (or the prospectus
relating thereto).

        11. TRANSFER OF REGISTRATION RIGHTS. None of the rights of any Investor
under this Agreement shall be transferred or assigned to any person unless (i)
such person is a Qualifying Holder (as defined below), and (ii) such person
agrees to become a party to, and bound by, all of the terms and conditions of,
this Agreement by duly executing and delivering to the Company an Instrument of
Adherence in the form attached as Exhibit B hereto.

                                       6.
<PAGE>   7

For purposes of this Section 11, the term "Qualifying Holder" shall mean, with
respect to any Investor, (i) any partner thereof, (ii) any corporation,
partnership controlling, controlled by, or under common control with, such
Investor or any partner thereof, or (iii) any other direct transferee from such
Investor of at least 50% of those Registrable Shares held or that may be
acquired by such Investor. None of the rights of any Investor under this
Agreement shall be transferred or assigned to any Person (including, without
limitation, a Qualifying Holder) that acquires Registrable Shares in the event
that and to the extent that such Person is eligible to resell such Registrable
Shares pursuant to Rule 144(k) of the Securities Act or may otherwise resell
such Registrable Shares pursuant to an exemption from the registration
provisions of the Securities Act.

        12. ENTIRE AGREEMENT. This Agreement constitutes and contains the entire
agreement and understanding of the parties with respect to the subject matter
hereof, and it also supersedes any and all prior negotiations, correspondence,
agreements or understandings with respect to the subject matter hereof.

        13. MISCELLANEOUS.

             (a) This Agreement may not be amended, modified or terminated, and
no rights or provisions may be waived, except with the written consent of the
Majority Holders and the Company.

             (b) This Agreement shall be governed by and construed and enforced
in accordance with the laws of the State of California, and shall be binding
upon and inure to the benefit of the parties hereto and their respective heirs,
personal representatives, successors or assigns, provided that the terms and
conditions of Section 11 hereof are satisfied. This Agreement shall also be
binding upon and inure to the benefit of any transferee of any of the Purchased
Shares provided that the terms and conditions of Section 11 hereof are
satisfied. Notwithstanding anything in this Agreement to the contrary, if at any
time any Investor shall cease to own any Purchased Shares, all of such
Investor's rights under this Agreement shall immediately terminate.

             (c)    (i) Any notices, response or other correspondence
(hereinafter collectively referred to as "correspondence") required or permitted
to be given hereunder shall be sent by courier (overnight or same day) or
telecopy or delivered by hand to the party to whom such correspondence is
required or permitted to be given hereunder. The date of giving any notice shall
be the date of its actual receipt.

                    (ii) All correspondence to the Company shall be addressed as
follows:

                                      Coulter Pharmaceutical, Inc.
                                      600 Gateway Blvd.
                                      South San Francisco, CA  94080
                                      Attention:  Michael F. Bigham
                                      Chief Executive Officer
                                      Telecopier:  650-553-2728

                                       7.
<PAGE>   8

                            with a copy to:

                                       Cooley Godward LLP
                                       5 Palo Alto Square
                                       Palo Alto, CA 94306
                                       Attention: James C. Kitch
                                       Telecopier: 650-849-7400

                    (iii) All correspondence to any Investor shall be sent to
such Purchaser at the address set forth in Exhibit A.

             (d) Any entity may change the address to which correspondence to it
is to be addressed by notification as provided for herein.

             (e) The parties acknowledge and agree that in the event of any
breach of this Agreement, remedies at law may be inadequate, and each of the
parties hereto shall be entitled to seek specific performance of the obligations
of the other parties hereto and such appropriate injunctive relief as may be
granted by a court of competent jurisdiction.

             (f) This Agreement may be executed in a number of counterparts, and
of which together shall for all purposes constitute one Agreement, binding on
all the parties hereto notwithstanding that all such parties have not signed the
same counterpart.

                  [REMAINDER OF PAGE LEFT INTENTIONALLY BLANK]

                                       8.
<PAGE>   9

        IN WITNESS WHEREOF, the parties hereto have executed this Registration
Rights Agreement as of the date and year first above written.

                                       COULTER PHARMACEUTICAL, INC.

                                       By:
                                          ------------------------------------

                                       Name:
                                            ----------------------------------

                                       Title:
                                             ---------------------------------

THE INITIAL INVESTOR'S SIGNATURE TO THE INVESTOR QUESTIONNAIRE DATED EVEN DATE
HEREWITH SHALL CONSTITUTE THE INTIAL INVESTOR'S SIGNATURE TO THIS REGISTRATION
RIGHTS AGREEMENT.

                                       9.
<PAGE>   10

                                    EXHIBIT A

INITIAL INVESTORS
----------------------------------------------------------
Alta Embarcadero BioPharma, LLC
Alta BioPharma Partners, LP
Coulter Pharmaceuticals Chase Partners (Alta Bio), LLC
Marcuard Cook & Cie, SA
Narragansett Offshore Ltd.
Narragansett I LP
Three Arch Partners III, L.P.
Three Arch Partners III, L.P.
The Timken Living Trust UAD 9/14/99
Baker / Tisch Investments LLC
Four Partners
FBB Associates
Baker Bros. Investments
Veritas SG Investment Trust GmbH
John Sullivan IRA
Herbert G. Roskind, Jr. IRA
Presbyterian Homes * Family Services, Inc.
International Truck & Engine Corp. - Hourly
International Truck & Engine Corp. - Salaried
International Truck & Engine Corp.- VEBA
The University of Mississippi
The University of Mississippi Medical  Center

The University of Mississippi Foundation
Michigan Botanic Garden Foundation
Meijer Foundation
Frederik Meijer Charitable Trust
ATP Tour Inc. Player Pension Plan
MJH Foundation
Commonfund Group
City of Springfield
Charlottesville, VA Retirement System

Meijer, Inc. Pension Plan

                                       1.
<PAGE>   11

INITIAL INVESTORS
----------------------------------------------------------
Bridgeport Hospital Pension
Bridgeport Hospital Foundation
Bridgewater College
Trustees of Boston College
University of Virginia
Richard M. Drury IRA
Joan P. Drury IRA
James B. & Bruce R. Murray
Ned's Island Investment Corp.
Joseph F. & Marlene M. Bonasera
Frederik G.H. Meijer Trust
Lena E. S. Meijer Trust
Laura C. Roskind
Wheaton College
Tremont Temple Baptist Church General Trust Fund
Tremont Temple Bobbie Currie Sunday School Fund
The Berkeley Retirement Home
Baillie Lumber Co. Inc. Profit Share Plan
Dows - First Calvary Baptist Church
Buzz Johnson, IRA
Society for the Preservation of New England Antiquities
The Evangelical Covenant Church Pension Fund
1101 Foundation
General Board of Church of Nazarene
St. Joseph Health System
Bryan N. Danforth #2
Jeffrey S. Meyer
Richard J. Tavilla
Kirk Ware
Dr. G. Timothy Johnson M.D., P.C., MPPP
Republic National Bank INSIGHT Funds

                                       2.
<PAGE>   12

                                    EXHIBIT B

                             INSTRUMENT OF ADHERENCE

        Reference is hereby made to that certain Registration Rights Agreement,
dated as of August __, 2000, among Coulter Pharmaceutical, Inc. a Delaware,
corporation (the "Company"), the Initial Investors and the Investor Permitted
Transferees, as amended and in effect from time to time (the "Registration
Rights Agreement"). Capitalized terms used herein without definition shall have
the respective meanings ascribed thereto in the Registration Rights Agreement.

        The undersigned, in order to become the owner or holder of [__________
shares of common stock, par value $0.001 per share (the "Common Stock"), of the
Company], hereby agrees that, from and after the date hereof, the undersigned
has become a party to the Registration Rights Agreement in the capacity of an
Investor Permitted Transferee, and is entitled to all of the benefits under, and
is subject to all of the obligations, restrictions and limitations set forth in,
the Registration Rights Agreement that are applicable to Investor Permitted
Transferees. This Instrument of Adherence shall take effect and shall become a
part of the Registration Rights Agreement immediately upon execution.

        Executed under seal as of the date set forth below under the laws
of_______________________________________________.

                                       Signature:
                                                 -------------------------------
                                                 Name:
                                                 Title:

Accepted:

Coulter Pharmaceutical, Inc.

By:
   -----------------------------------
    Name: Michael F. Bigham
    Title: Chief Executive Officer

Date:
     ---------------------

                                       1.<PAGE>   1

                                                                    EXHIBIT 10.1

                   SUBSCRIPTION AND SHARE PURCHASE AGREEMENT

         This Subscription and Share Purchase Agreement (this "Agreement") is
made and entered into as of the date set forth on the acceptance page among
Freerealtime.com, Inc., a Delaware corporation (the "Company"), and the persons
and entities listed on Schedule 1 attached hereto who are signatories to this
Agreement (the "Investors").

                                    RECITALS

         The Company has authorized the issuance and sale of 3,810,367 shares
(the "Offering") of its common stock, par value $0.01 per share (the "Shares").

SECTION 1. AGREEMENT TO SUBSCRIBE; PAYMENT; TERMS OF SUBSCRIPTION.

         1.1 Subscription. Each Investor hereby irrevocably subscribes for such
number of Shares as is set forth opposite such Investor's name on Schedule 1, at
a price of $2.625 per Share. Each Investor has submitted to the Company by
either wire transfer or by a check payable to "Freerealtime.com, Inc." in the
full amount of the purchase price, the purchase price for the Shares for which
such Investor is subscribing (the "Purchase Price").

         1.2 Payment. Each Investor understands that the Company may utilize the
Purchase Price immediately upon the Closing (as defined in Section 2.2 below)
which shall occur at any time after the Company has accepted a minimum of $7.5
million in subscriptions from Investors. Prior to the Closing, Investor proceeds
shall be deposited in an interest bearing escrow account and the interest, if
any, earned on such funds prior to acceptance of the Investor's subscription by
the Company will be paid to the Company upon the Closing, or shall be
distributed to the Investor if the Offering is terminated or the Investor's
subscription is not accepted by the Company. In addition, if the Company
consummates the Offering and only accepts a portion of the Investor's
subscription, the Company will retain the interest, if any, earned on such funds
in proportion to the amount of the subscription accepted and shall distribute
the remaining amount of interest, as well as the unaccepted portion of the
Purchase Price to the Investor promptly following the Closing.

         1.3 Terms of Subscription. Each Investor further understands that,
except as provided under any applicable state securities laws or as expressly
provided herein, (i) this subscription may not be revoked by such Investor, (ii)
the execution and delivery of this Agreement by the Investor will not constitute
an agreement between the Investor and the Company until this Agreement has been
accepted by the Company evidenced by receipt by the Investor of a signed
acceptance page by the Company of this Agreement, and then subject to the terms
and conditions of this Agreement, and (iii) this subscription may be accepted or
rejected in whole or in part by the Company, in its sole and absolute discretion
for any reason whatsoever and the Offering may be withdrawn prior to any
acceptance of subscriptions received.

SECTION 2. SALE OF SHARES; CLOSING.

         2.1 Sale of Shares. Subject to the terms and conditions of this
Agreement, the Company will issue and sell to each Investor whose subscription
for Shares has been accepted by the Company, and each such Investor will buy
from the Company, the number of Shares of the

<PAGE>   2

Company set forth opposite such Investor's name on Schedule 1, (or such lesser
number as is accepted by the Company) at a purchase price of $2.625 per Share.
The Company's agreement with each such Investor is a separate agreement and the
sale of the Shares to each Investor is a separate sale.

         2.2 Closing Date. The closing of the purchase and sale of the Shares
hereunder (the "Closing") shall be held at the offices of Latham & Watkins, 650
Town Center Drive, 20th Floor, Costa Mesa, California 92626, at a time and on a
date specified in a written notice from the Company to each of the Investors
(the date of the Closing being hereinafter referred to as the "Closing Date").

         2.3 Delivery at Closing. At the Closing, the Company will deliver to
each Investor a stock certificate representing the Shares registered in such
Investor's name as set forth on Schedule 1.

SECTION 3. REPRESENTATIONS AND WARRANTIES OF THE COMPANY.

         The Company represents and warrants to the Investors as follows:

         3.1 Valid Issuance of the Shares. The Shares, when issued in accordance
with the terms hereof will be duly and validly issued, fully-paid and
nonassessable and, based in part upon the representations of the Investors in
this Agreement, will be issued in compliance with all applicable federal and
state securities laws regarding registration or qualification.

         3.2 Organization, Good Standing and Qualification. The Company is a
corporation duly organized, validly existing and in good standing under the laws
of the State of Delaware and has all requisite corporate power and authority to
own and operate its properties and assets and to carry on its business as now
conducted and as proposed to be conducted. The Company is duly qualified to
transact business and is in good standing in each jurisdiction in which the
failure to so qualify would have an adverse effect on its business, properties,
or financial condition.

         3.3 Capitalization. The authorized and outstanding capitalization of
the Company consists of the following:

         (a) Authorized and Outstanding Common Stock. The Company's Certificate
of Incorporation authorizes the issuance of 50,000,000 shares of Common Stock of
the Company (the "Common Stock"), of which 7,615,481 are issued and outstanding
as of the date of this Agreement. The outstanding shares of Common Stock have
been duly authorized, validly issued, are fully paid and nonassessable, and were
issued in accordance with the registration and qualification provisions of the
Securities Act of 1933, as amended (the "Act") and any relevant state securities
laws or pursuant to valid exemptions therefrom.

         (b) Authorized and Outstanding Preferred Stock. The Company's
Certificate of Incorporation authorizes the issuance of 5,000,000 shares of
Preferred Stock of the Company (the "Preferred Stock"), of which no shares are
issued and outstanding as of the date of this Agreement.

                                       2
<PAGE>   3

         3.4 Convertible Securities, Options, Warrants and Rights. Except for
(i) 2,500,000 shares of Common Stock are reserved for issuance to existing and
future employees, directors, consultants, vendors and advisors of the Company
under the Company's 1999 Equity Incentive Plan, (ii) 182,500 shares of Common
Stock reserved for issuance upon the exercise of outstanding warrants and (iii)
the Agreement and Plan of Merger by and between the Company and RedChip.com,
Inc. dated as of June 6, 2000, there are no outstanding convertible securities,
options, warrants, rights (including conversion or preemptive rights) or
agreements for the purchase or acquisition from the Company of any shares of its
capital stock.

         3.5 Voting Agreements. The Company is not a party or subject to any
agreement or understanding, and, to the Company's best knowledge, there is no
agreement or understanding between any individuals and/or entities, which
affects or relates to the voting or giving of written consents with respect to
any of the Company's voting securities.

         3.6 Authorization. The Company has all corporate and other requisite
authority to execute, deliver and carry out and perform the obligations under
the terms of this Agreement and all of the transactions contemplated hereby,
including the sale and issuance of the Shares. This Agreement, when executed and
delivered by the Company, will constitute a valid and binding obligation of the
Company, enforceable against the Company in accordance with its terms.

         3.7 Registration Rights. Except as set forth in Schedule 3.7 and in the
Investor Rights Agreement entered into by and between the Company and the
Investors substantially in the form attached hereto as Exhibit 3.7 which the
parties shall enter into as of the Closing Date, the Company is not a party to
any agreement or commitment which obligates the Company to register under the
Act, any if its presently outstanding securities or any of its securities which
may hereafter be issued.

         3.8 Private Offering.

         (a) The Company has offered the Shares hereunder in reliance on
exemptions from the registration and prospectus delivery requirements of the
Act. Each Share certificate shall bear the legend substantially in the form set
forth in Section 5.2(b) of this Agreement relating to the restrictions on
transferability and sale imposed by the Act for at least so long as such
restrictions apply.

         (b) In the case of each offer or sale of the Shares, no form of general
solicitation or general advertising was used by the Company or its
representatives, including, but not limited to, advertisements, articles,
notices or other communications published in any newspaper, magazine or similar
medium or broadcast over television or radio, or any seminar or meeting whose
attendees were invited by any general solicitation or general advertising. Each
Investor has represented to the Company that such Investor is an accredited
investor or an entity in which all of the equity owners are accredited
investors.

         3.9 No Violation. Neither the execution, delivery or performance of
this Agreement nor the consummation of the transactions contemplated hereby and
thereby, nor compliance by the Company with any of the provisions hereof, will
(a) violate or conflict with

                                       3
<PAGE>   4

any provision of the Certificate of Incorporation or Bylaws of the Company, (b)
violate, conflict with, or result in or constitute a default under, or result in
the termination of, or accelerate the performance required by, or result in a
right of termination or acceleration under, or result in the creation of any
encumbrance upon any of the Company's assets under, any of the terms, conditions
or provisions of any of the Company's material contracts (as set forth in the
exhibit list of the Company's Form 10-KSB, filed on June 29, 2000 for the Fiscal
Year ended March 31, 2000 (the "Company's 10-KSB"), (c) violate any regulation
or court order to which the Company is bound, or (d) impose any encumbrance on
the Company's assets or business except, in each case, where such violation,
conflict, default, termination, acceleration, or encumbrance would not have a
material adverse effect on the Company.

         3.10 Litigation. There are no actions, suits, proceedings, or
investigations pending against the Company or, to the best knowledge of the
Company, any basis therefor or threat thereof and the Company is not a party or
subject to the provisions of any order, writ, injunction, judgment or decree of
any court or government agency or instrumentality which would have a material
effect on the Company or its business. To the best of the Company's knowledge,
the Company is not in violation of any applicable statue, law or regulation
relating to the environment or occupational health and safety where such
violation would have a material adverse effect on the Company, and no material
expenditures will be required in order to comply with any such existing statue,
law or regulation.

         3.11 Financial Statements. The Company's audited financial statements
set forth in the Company's 10-KSB (the "Financial Statements") have been
prepared in accordance with generally accepted accounting principles ("GAAP")
applied on a consistent basis throughout the periods indicated and with each
other and fairly present the financial condition of the Company as of such dates
and the results of operations of the Company for the periods covered thereby.
Since March 31, 2000 there has not been any material adverse change to the
financial condition or results of operations of the Company as set forth in the
Financial Statements. There are no material liabilities required by GAAP to be
disclosed in the Financial Statements which are not disclosed in the Financial
Statements. Except as disclosed in the Financial Statements, the Company is not
a guarantor or indemnitor of any indebtedness of any other Person. The Company
maintains and will continue to maintain a standard system of accounting
established and administered in accordance with GAAP.

         3.12 Taxes. The Company has filed all tax returns and reports as
required by law. These returns and reports are true and correct in all material
respects. The Company has paid all taxes and other assessments due. The Company
has never had a tax deficiency proposed or assessed against it and has not
executed any waiver of any statute of limitations on the assessment or
collection of any tax or governmental charge. Since the date of the Financial
Statements, the Company has made adequate provisions on its books to account for
all taxes, assessments, and governmental charges with respect to its business,
properties and operations for such period. The Company has withheld or collected
from each payment made to each of its employees, the amount of all necessary
taxes and required withholdings, and has paid the same to the proper tax
receiving officers or authorized depositories.

         3.13 Proprietary Rights. The Proprietary Rights of the Company are all
those necessary for the normal conduct of the Company's business as presently
conducted and as

                                       4
<PAGE>   5

presently contemplated, including the design, manufacture and sale of all
products currently under development, planned for development or in production.
The Company owns or has a valid right to use its Proprietary Rights, and such
Proprietary Rights will not cease to be valid rights of the Company by reason of
the execution, delivery and performance of this Agreement or the consummation of
the transactions contemplated hereby. For purposes of this Section 3.13, the
term "Proprietary Rights" shall mean all (a) U.S. and foreign patents, patent
applications, patent disclosures and improvements thereto, including petty
patents and utility models and applications therefor, (b) U.S. and foreign
trademarks, service marks, trade dress, logos, trade names and corporate names
and the goodwill associated therewith and registrations and applications for
registration thereof, (c) U.S. and foreign copyrights and registrations and
applications for registration thereof, (d) U.S. and foreign mask work rights and
registrations and applications for registration thereof, (e) Trade Secrets, (f)
URL registrations, (g) other proprietary rights, (h) copies and tangible
embodiments thereof (in whatever form or medium) and (i) licenses granting any
rights with respect to any of the foregoing.

         3.14 Private Placement Memorandum. Neither this Agreement nor the
Offering Memorandum contains any untrue statement of a material fact or omits to
state a material fact necessary to make the statements herein or therein not
misleading.

SECTION 4. REPRESENTATIONS AND WARRANTIES OF THE INVESTORS.

         Each Investor individually represents, warrants, acknowledges and
agrees that:

         4.1 Authorization. This Agreement constitutes such Investor's legally
binding and valid obligation, enforceable in accordance with its terms, and each
Investor has full power and authority to enter into this Agreement.

         4.2 Restricted Securities.

         (a) Such Investor understands that the Shares are "restricted
securities" under the Act and that, under the Act and applicable regulations
thereunder, such securities may not be resold, pledged or otherwise transferred
without registration under the Act except in certain limited circumstances. Each
Investor understands that (i) the Shares are being offered in a transaction not
involving any public offering in the United States within the meaning of the
Act, and the Shares have not been registered under the Act, (ii) such Shares may
be offered, resold, pledged or otherwise transferred only in a transaction
meeting the requirements of Rule 144, or in accordance with another exemption
from the registration requirements of the Act (and based upon an opinion of
counsel if the Company so requests) in accordance with any applicable securities
laws of any State of the United States or any other applicable jurisdiction, and
(iii) such Investor will be required to notify any subsequent purchaser from
such Investor of the resale restrictions set forth above.

         (b) Such Investor understands that (i) the registrar or transfer agents
for the Shares will not be required to accept for registration of transfer any
Shares except upon presentation of evidence satisfactory to the Company that the
restrictions on transfer under the Act have been complied with and (ii) any
Shares in the form of definitive physical certificates will bear a legend
substantially as set forth below:

                                       5
<PAGE>   6

         THE SECURITIES EVIDENCED HEREBY WERE ORIGINALLY ISSUED IN A TRANSACTION
         EXEMPT FROM REGISTRATION UNDER SECTION 5 OF THE UNITED STATES
         SECURITIES ACT OF 1933 (THE "SECURITIES ACT") AND APPLICABLE STATE
         SECURITIES LAWS, AND THE SECURITIES EVIDENCED HEREBY MAY NOT BE
         OFFERED, SOLD OR OTHERWISE TRANSFERRED IN THE ABSENCE OF SUCH
         REGISTRATION OR AN APPLICABLE EXEMPTION THEREFROM. THE HOLDER OF THE
         SECURITIES EVIDENCED HEREBY AGREES FOR THE BENEFIT OF THE CORPORATION
         THAT (A) SUCH SECURITIES MAY NOT BE RESOLD, PLEDGED OR OTHERWISE
         TRANSFERRED, EXCEPT (1) IN A TRANSACTION MEETING THE REQUIREMENTS OF
         RULE 144 UNDER THE SECURITIES ACT, OR IN ACCORDANCE WITH ANOTHER
         EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT (AND
         BASED UPON AN OPINION OF COUNSEL IF THE CORPORATION SO REQUESTS), (2)
         TO THE CORPORATION, OR (3) PURSUANT TO AN EFFECTIVE REGISTRATION
         STATEMENT UNDER THE SECURITIES ACT, IN EACH CASE, IN ACCORDANCE WITH
         THE APPLICABLE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES OR ANY
         OTHER APPLICABLE JURISDICTION AND (B) THE HOLDER WILL, AND EACH
         SUBSEQUENT HOLDER IS REQUIRED TO, NOTIFY ANY PURCHASER OF THE
         SECURITIES EVIDENCED HEREBY OF THE RESALE RESTRICTIONS SET FORTH IN (A)
         ABOVE.

         4.3 Accredited Investor.

         (a) Such Investor is an "accredited investor" within the meaning of
Rule 501(a) under the Act or an entity in which all of the equity owners are
accredited investors within the meaning of Rule 501(a) (1),(2) or (3) under the
Act (an "Institutional Accredited Investor").

         (b) (i) Such Investor is purchasing the Shares for its own account or
for the account of one or more other Institutional Accredited Investors or as
fiduciary for the account of one or more trusts, each of which is an "accredited
investor" within the meaning of Rule 501(a)(7) under the Act and for each of
which it exercises sole investment discretion or (ii) such Investor is a "bank,"
within the meaning of Section 3(a)(2) of the Act, or a "savings and loan
association" or other institution described in Section 3(a)(5)(A) of the Act
that is acquiring the Shares as fiduciary for the account of one or more
Institutional Accredited Investors for which such Investor exercises sole
investment discretion. Each Investor has such knowledge and experience in
financial and business matters that such Investor is capable of evaluating the
merits and risks of purchasing the Shares.

         (c) Such Investor is not acquiring the Shares with a view to any
distribution thereof in a transaction that would violate the Act or the
securities laws of any State of the United States or any other applicable
jurisdiction; provided, however, that the disposition of such Investor's
property and the property of any accounts for which such Investor is acting as
fiduciary shall remain at all times within such Investor's control.

                                       6
<PAGE>   7

         (d) Such Investor acknowledges that it has had access to such financial
and other information, and has been afforded the opportunity to ask such
questions of representatives of the Company and receive answers thereto, as such
Investor deems necessary in connection with its decision to purchase the Shares.

         (e) Such Investor acknowledges that a purchase of the Shares involves
certain risks, which include, among other factors, that: (i) the Company has a
limited operating history; (ii) the purchase of the Shares is a speculative
investment and involves a high degree of risk of loss; (iii) the Company will be
engaged in a business which is highly competitive; (iv) the Company may issue
additional equity securities in the future and, accordingly, such Investor's
investment in the Company will be subject to dilution; and (v) there are
substantial restrictions on the transferability of, and there may be no public
market for, the Shares and, accordingly, it may not be possible for such
Investor to liquidate the Shares in case of the imminent need of funds or any
other emergency. Such Investor and any advisor(s) of such Investor understand
such risks.

         (f) Such Investor confirms that, except as specifically set forth
herein, neither the Company nor any of its agents (including members of its
Board of Directors) have made any representations or warranties concerning the
Company, including, without limitation, any representations or warranties
concerning anticipated financial results of the operations of the Company. Such
Investor understands and agrees that any such plans, summaries and projections
may provide no assurance of the Company's future performance and may prove to be
materially incomplete and inaccurate and are not to be relied upon in making
this investment decision. Such Investor further understands that any financial
projections, results or forecasts delivered to such Investor should not be
relied upon to indicate the actual financial results that will be achieved by
the Company.

         (g) If such Investor is an individual, such Investor is a resident and
domiciliary of the state or other jurisdiction set forth on the signature page
hereto and has no present intention of becoming a resident of any other state or
jurisdiction. If such Investor is an entity, its domicile and principal office
is located in the state or jurisdiction set forth on the signature page hereto
and has no present intention of changing the location of such domicile and
principal office to another state or jurisdiction.

         (h) Such Investor acknowledges and agrees that Latham & Watkins, for
the purposes of any opinion to be delivered in connection with the offering and
sale of securities hereby, may rely on the truthfulness of its representations
set forth in Section 4.

         4.4 Brokerage. Other than Jefferies & Company, Inc., and Roth Capital
Partners (the "Placement Agents"), the Investor has not dealt with, or incurred
liability for a fee to, any finder, broker, investment banker or financial
advisor in connection with any of the transactions contemplated by this
Agreement or the negotiations looking toward the consummation of such
transactions.

                                       7
<PAGE>   8

SECTION 5. CONDITIONS OF CLOSING.

         5.1 Conditions to Investors' Obligations. The obligations of each
Investor under Section 2 of this Agreement are subject to the fulfillment at or
before the Closing of each of the following conditions, any of which may be
waived in writing by an Investor:

         (a) Representations and Warranties. The representations and warranties
of the Company contained in Section 3 shall be true on and as of the Closing
with the same effect as if made on and as of the Closing.

         (b) Performance. The Company shall have performed or fulfilled all
agreements, obligations and conditions contained herein required to be performed
or fulfilled by the Company at or prior to the Closing.

         (c) Blue Sky Compliance. The purchase of and payment for the Shares to
be purchased (a) shall not be prohibited by any applicable law or governmental
regulation, release or interpretation, and (b) shall be permitted by the laws
and regulations of the jurisdictions to which such Investor is subject. The
Company shall have delivered to each Investor, upon its reasonable request,
factual certificates or other evidence, in form and substance satisfactory to
such Investor, to enable it to establish compliance with this condition.

         (d) Closing Documents. The Company shall have delivered to the
Investors, unless waived in writing by the Investors:

                  (i) Copies (certified by the President or Secretary of the
Company) of the resolutions duly adopted by the Board of Directors of the
Company authorizing the execution, delivery and performance of this Agreement
and the Other Agreements contemplated hereby;

                  (ii) A copy (certified by the Secretary of the State of
Delaware) of the Company's Certificate of Incorporation as amended through the
date of the Closing and a copy (certified by the President or Secretary of the
Company) of the Bylaws as amended through the date of the Closing;

                  (iii) A certificate of the President and the Chief Financial
Officer of the Company confirming that the Representations and Warranties
contained in Section 3 are correct and that all the conditions in Section 5.2
have been satisfied;

                  (iv) Such other documents relating to the transactions
contemplated by this Agreement as the Investors or the Investors' counsel may
reasonably request.

                  (v) Opinion of Company Counsel. At the Closing the Investors
shall have received the opinion of Latham & Watkins, counsel to the Company, in
substantially the form set forth at the Closing as Exhibit 5.1(d)(v) to this
Agreement.

         5.2 Conditions to the Company's Obligations. The obligations of the
Company under Section 2 of this Agreement are subject to the fulfillment at or
before the Closing of each of the following conditions, any of which may be
waived in writing by the Company:

                                       8
<PAGE>   9

         (a) Placement Agent Certificates. The Company shall have received a
certificate, reasonably satisfactory to the Company, from each placement agent,
if any, in the Offering to the effect that no form of general solicitation or
general advertising was used by such placement agent or its representatives in
connection with the Offering, including, but not limited to, advertisements,
articles, notices or other communications published in any newspaper, magazine
or similar medium or broadcast over television or radio, or any seminar or
meeting whose attendees were invited by any general solicitation or general
advertising.

         (b) Representations and Warranties. The representations and warranties
of the Investors contained in Section 4 shall be true on and as of the Closing
with the same effect as if made on and as of the Closing.

         (c) Payment of Purchase Price. Each Investor shall have delivered the
aggregate purchase price for the Shares in the amount specified for such
Investor on Schedule 1.

         (d) Blue Sky Matters. The purchase of and payment for the Shares to be
purchased (a) shall not be prohibited by any applicable law or governmental
regulation, release or interpretation, and (b) shall be permitted by the laws
and regulations of the jurisdictions to which the Investors are subject.

SECTION 6. COVENANTS OF THE COMPANY.

         6.1 Preservation of Exemption. Neither the Company nor any authorized
agent acting on its behalf will take any action hereafter that would cause the
loss of the exemption from the registration requirements of the Act relied upon
for the offer and sale of the Common Stock.

         6.2 Legends. The Investors agree that the Company may place or cause to
be placed on the certificates representing the securities, the legend set forth
in Section 4.2(b) hereof regarding the restriction on transfer and any
appropriate legend or legends containing restrictions on transfer necessary
under the Act and any other applicable state corporations or securities statutes
and regulations.

         6.3 Board Representation. The Company shall nominate a person
designated by Jefferies & Company, Inc. ("Jefferies") to be a member of the
Board of Directors of the Company at the first annual or special meeting of
stockholders to occur after the Closing, and at each annual meeting of
stockholders thereafter so long as Jefferies or its affiliates continue to hold
at least 500,000 shares of the Company's Common Stock.

SECTION 7. EXPENSES; INDEMNIFICATION.

         7.1 Expenses. Whether or not the Shares are sold, the Company will pay
the following expenses relating to this Agreement:

         (a) the cost of printing (including, without limitation, word
processing and duplication costs), reproducing and distributing this Agreement
and any other documents contemplated hereby or thereby;

                                       9
<PAGE>   10

         (b) the fees, disbursements and expenses of the Company's counsel and
accountants; and

         (c) all other expenses incurred by the Company in connection with the
transactions contemplated by this Agreement and the other documents contemplated
by this transaction.

         7.2 Indemnification. The Company and the Investor each agree to
indemnify and hold the other party, its officers, directors and stockholders or
any other person who may be deemed to control such other party harmless from any
loss, liability, claim, damage or expense, arising out of the inaccuracy of any
of the representations, warranties or statements of such indemnifying party or
the breach of any of the agreements of such indemnifying party contained herein
and this indemnification shall survive the purchase and sale of Shares under
this Agreement.

SECTION 8. MISCELLANEOUS.

         8.1 Entire Agreement; Successors and Assigns. This Agreement, together
with its exhibits and schedules, constitutes the entire contract between the
Company and the Investors relative to the subject matter hereof. Any previous
agreement between the Company and the Investors is superseded by this Agreement.
Subject to the exceptions specifically set forth in this Agreement, the terms
and conditions of this Agreement shall inure to the benefit of and be binding
upon the respective executors, administrators, heirs, successors and assigns of
the parties.

         8.2 Further Action. During the period from the date hereof to the
Closing, the Company shall use its best efforts and take all action reasonably
necessary or appropriate to cause its representations and warranties contained
in Section 4 of this Agreement to be true as of the Closing Date, after giving
effect to the transactions contemplated by this Agreement, as if made on and as
of such date.

         8.3 Governing Law. This Agreement shall be governed by and construed in
accordance with the laws of the State of Delaware without regard to its
conflicts of law principles.

         8.4 Counterparts. This Agreement may be executed in several
counterparts, each or which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

         8.5 Headings. The headings of the Sections of this Agreement are for
convenience and shall not by themselves determine the interpretation of this
Agreement.

         8.6 Notices. Prior to the Closing, and thereafter with respect to
matters pertaining to this Agreement only, all notices and other communications
provided for or permitted hereunder shall be made by hand-delivery, first-class
mail (registered or certified, return receipt requested), telex, telecopier, or
overnight air courier guaranteeing next day

                                       10
<PAGE>   11

delivery to the following addresses or numbers or to such other addresses or
numbers as shall be provided in a notice given in accordance with this Section:

         (a) if to the Investors, at such addresses set forth on the counterpart
signature page attached hereto;

         (b) if to the Company, at Freerealtime.com, Inc., 3333 Michelson Drive,
Suite 430, Irvine, CA 92612, Attention: General Counsel, Facsimile No: (949)
833-7665, with a copy to Latham & Watkins, 650 Town Center Drive, 20th Floor,
Costa Mesa, California 92626, Attention: Cary K. Hyden, Esq., Facsimile No.:
(714) 755-8290.

         All such notices and communications shall be deemed to have been duly
given: at the time delivered by hand, if personally delivered; five business
days after being deposited in the mail, postage prepaid, if mailed; when
answered back, if telexed; when receipt acknowledged, if telecopied; and the
next business day after timely delivery to the courier, if sent by overnight air
courier guaranteeing next day delivery.

         8.7 Survival of Representations and Warranties. The covenants,
agreements, representations and warranties of the parties contained in or made
pursuant to this Agreement shall survive the execution and delivery of this
Agreement and the Closing; provided, however, that such representations and
warranties are only made as of the date of such execution and delivery and as of
the Closing.

         8.8 Amendments and Waivers. Prior to the Closing Date, this Agreement
may be amended, modified or supplemented, and waivers or consents to departures
from the provisions may be given, provided that the same are in writing and
signed by each Investor and the Company. Thereafter, this Agreement may only be
amended, and such waivers be given, with the consent of the Company and the
holders of a majority of the then outstanding shares of the Shares.

         8.9 Confidentiality; No Press Releases. Each Investor will, and will
cause each of its affiliates, advisors and representatives to, maintain this
Agreement and all information relating to the transactions contemplated hereby
(the "Confidential Information") in confidence and will not, and will cause each
of its advisors, affiliates and representatives not to, issue or cause the
publication of any press release or other public announcement with respect to
this Agreement, the transactions contemplated hereby or any other matter
communicated to the Investor by the Company or its representatives without the
prior written consent of the Company, which consent shall not be unreasonably
withheld. The foregoing restrictions shall not extend to any portion of the
Confidential Information which (a) can be shown by the Investor or any Recipient
to have been in its possession prior to disclosure to it by the Company or the
Investor,(b) is now or hereafter becomes, through no act or failure to act on
the part of the Investor or any Recipient, generally known to the public on a
non-confidential basis; or (c) is required by order or request of any
government, regulatory or self-regulatory body to be disclosed, but only to the
extent required by such order or request. The Investor shall promptly notify the
Company of any such request or order and shall assist the Company in seeking a
protective order or other appropriate remedy at the Company's sole cost and
expense.

                                       11
<PAGE>   12

         8.10 Severability. If one or more provisions of this Agreement are held
to be unenforceable under applicable law, such provision(s) shall be excluded
from this Agreement and the balance of this Agreement shall be interpreted as if
such provision were excluded and shall be enforceable in accordance with its
terms.

         8.11 Access to Information. The Company shall, from time to time prior
to the Closing, provide to each Investor such other information respecting the
business, operations, financial condition or assets of the Company or any
subsidiary of the Company as such Investor may reasonably request.

         8.12 Taxpayer Identification Number and Backup Withholding. Each
Investor verifies under penalties of perjury, that the Social Security
Number/Taxpayer Identification Number shown for such Investor on the counterpart
signature page to this Agreement is true, correct and complete and that the
Investor is not subject to backup withholding because either (a) the Investor is
exempt from backup withholding, or (b) the Investor has not been notified that
it is subject to backup withholding as a result of a failure to report all
interest or dividends, or (c) because the Internal Revenue Service has notified
the Investor that it is no longer subject to backup withholding.

         If this Agreement is satisfactory, please so indicate by signing and
delivering a counterpart signature page attached hereto. EXECUTION OF THE
COUNTERPART SIGNATURE PAGE CONSTITUTES THE EXECUTION BY THE INVESTOR OF THIS
SUBSCRIPTION AND SHARE PURCHASE AGREEMENT.

                            [SIGNATURE PAGES FOLLOW]

                                       12
<PAGE>   13

                             FREEREALTIME.COM, INC.
                    SUBSCRIPTION AND SHARE PURCHASE AGREEMENT
                           COUNTERPART SIGNATURE PAGES
                           (FOR INDIVIDUAL INVESTORS)

------------------------------------        ------------------------------------
PRINT NAME OF INVESTOR                      SIGNATURE OF INVESTOR

------------------------------------        ------------------------------------
PRINT NAME OF SPOUSE IF CO-OWNER            SIGNATURE OF SPOUSE IF CO-OWNER

Address:

------------------------------------

------------------------------------

------------------------------------

Telephone:
          --------------------------

Social Security or Taxpayer I.D. Number:

------------------------------------

State of Residence (if different from above):

------------------------------------

                                            ------------------------------------
                                            Number of Shares Subscribed for

                                            $
                                             -----------------------------------
                                             Amount Enclosed

                                      S-1
<PAGE>   14

                             FREEREALTIME.COM, INC.
                    SUBSCRIPTION AND SHARE PURCHASE AGREEMENT
                           COUNTERPART SIGNATURE PAGES
                   (FOR CORPORATION OR PARTNERSHIP INVESTORS)

                                        By:
------------------------------------        ------------------------------------
   PRINT NAME OF CORPORATION OR                   SIGNATURE OF OFFICER OR
           PARTNERSHIP                             AUTHORIZED SIGNATORY

                                        Name:
                                             -----------------------------------

                                        Title:
                                              ----------------------------------

Address:

------------------------------------

------------------------------------

------------------------------------

Telephone:
          --------------------------

Taxpayer I.D. Number:

------------------------------------

State of Incorporation:

------------------------------------

                                            ------------------------------------
                                            Number of Shares Subscribed for

                                            $
                                             -----------------------------------
                                             Amount Enclosed

                                      S-2
<PAGE>   15

                             FREEREALTIME.COM, INC.
                    SUBSCRIPTION AND SHARE PURCHASE AGREEMENT
                           COUNTERPART SIGNATURE PAGES
                         (FOR RETIREMENT PLAN INVESTORS)

------------------------------------        ------------------------------------
PRINT NAME OF RETIREMENT PLAN               SIGNATURE OF AUTHORIZED SIGNATORY

                                        Name:
                                             -----------------------------------

                                        Title:
                                              ----------------------------------

Address:

------------------------------------

------------------------------------

------------------------------------

Telephone:
          --------------------------

Taxpayer I.D. Number:

------------------------------------

                                            ------------------------------------
                                            Number of Shares Subscribed for

                                            $
                                             -----------------------------------
                                             Amount Enclosed

                                      S-3
<PAGE>   16

                             FREEREALTIME.COM, INC.
                    SUBSCRIPTION AND SHARE PURCHASE AGREEMENT
                           COUNTERPART SIGNATURE PAGES
                              (FOR TRUST INVESTORS)

Please Type or Print the Exact Legal
Title of Trust including, the Trustee's
name, and the date of Trust.

------------------------------------        ------------------------------------
                                            SIGNATURE OF TRUSTEE
------------------------------------
TITLE OF TRUST

                                            ------------------------------------
                                            PRINT NAME OF TRUSTEE

                                            ------------------------------------
                                            SIGNATURE OF TRUSTEE

                                            ------------------------------------
                                            PRINT NAME OF TRUSTEE

Address:

------------------------------------

------------------------------------

------------------------------------
Telephone:
          --------------------------

Social Security or Taxpayer I.D. Number:

------------------------------------
                                            ------------------------------------
                                            Number of Shares Subscribed for

                                            $
                                             -----------------------------------
                                             Amount Enclosed

                                      S-4
<PAGE>   17

                                   ACCEPTANCE

                  IN WITNESS WHEREOF, the Company has duly executed and
delivered this Subscription and Share Purchase Agreement as of August 15, 2000.

                                       FREEREALTIME.COM, INC.,
                                       a Delaware corporation

                                       By: /s/ Michael Neufeld
                                           -------------------------------------
                                           Name: Michael Neufeld
                                           Title: CFO

                                      S-6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00014-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00014-of-00352.parquet"}]]